Repligen Co. (RGEN) Shares Bought by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 0.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 129,477 shares of the biotechnology company’s stock after buying an additional 1,169 shares during the period. Rhumbline Advisers’ holdings in Repligen were worth $7,650,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Advisory Services Network LLC boosted its stake in Repligen by 10.7% during the fourth quarter. Advisory Services Network LLC now owns 1,771 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 171 shares during the period. Shelton Capital Management boosted its stake in Repligen by 4.7% during the fourth quarter. Shelton Capital Management now owns 3,949 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 179 shares during the period. Arizona State Retirement System boosted its stake in Repligen by 0.3% during the first quarter. Arizona State Retirement System now owns 60,301 shares of the biotechnology company’s stock valued at $3,563,000 after buying an additional 188 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in Repligen by 16.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 214 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its stake in Repligen by 14.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 2,385 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 292 shares during the period. 84.99% of the stock is owned by institutional investors.

RGEN has been the subject of several research analyst reports. Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $80.00 price target for the company in a research note on Tuesday, May 14th. ValuEngine lowered Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Finally, BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $64.20.

Shares of RGEN stock opened at $68.52 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. Repligen Co. has a 12-month low of $41.88 and a 12-month high of $71.21. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of 93.86, a PEG ratio of 4.19 and a beta of 1.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The firm had revenue of $60.63 million during the quarter, compared to analyst estimates of $55.09 million. During the same quarter in the previous year, the company posted $0.17 earnings per share. The company’s revenue was up 35.3% compared to the same quarter last year. Equities research analysts anticipate that Repligen Co. will post 0.94 earnings per share for the current fiscal year.

In other Repligen news, CFO Jon Snodgres sold 1,875 shares of Repligen stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $58.88, for a total transaction of $110,400.00. Following the completion of the sale, the chief financial officer now owns 26,821 shares of the company’s stock, valued at $1,579,220.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 7,475 shares of Repligen stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $59.01, for a total value of $441,099.75. Following the completion of the transaction, the chief executive officer now owns 250,132 shares in the company, valued at approximately $14,760,289.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,437 shares of company stock valued at $2,855,032. Corporate insiders own 1.70% of the company’s stock.

WARNING: “Repligen Co. (RGEN) Shares Bought by Rhumbline Advisers” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/repligen-co-rgen-shares-bought-by-rhumbline-advisers.html.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.